(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Health Care Sector

Lucintel Forecasts Primary Cell Market to Grow at a CAGR of 7%-9%

September 12th, 2021

Dallas, TX / CRWE PRESS RELEASE / Sep. 12, 2021 -  According to the recent study the primary cell market is projected to grow at a CAGR of 7%-9% from 2020 to 2025. Growth in this market is primarily driven by increasing cancer research and rapid. Read more

Lucintel Forecasts Magnetite Market to Reach $130.8 Billion by 2026

August 16th, 2021

Dallas, TX / CRWE PRESS RELEASE / Aug. 16, 2021 - According to the recent study the magnetite market is projected to reach an estimated $130.8 billion by 2026 from $98.2 billion in 2020, at a CAGR of 5% from 2020 to 2026. Growth in this market is pri. Read more

Lucintel Forecasts 3D Printing Medical Device Market to Reach $4.5 Billion by 2026

August 16th, 2021

Dallas, TX / CRWE PRESS RELEASE / Aug. 16, 2021 - According to the recent study the 3D printing medical device market is projected to reach an estimated $4.5 billion by 2026 from $0.7 billion in 2020, at a CAGR of 36% from 2020 to 2026. Growth in thi. Read more

Lucintel Forecasts Diagnostic Imaging Market to Reach $119 Billion by 2025

April 28th, 2021

Dallas, TX / CRWE PRESS RELEASE / April 28, 2021 - According to the recent study the diagnostic imaging market is projected to reach an estimated $33.1 billion by 2025 from $29.3 billion in 2019, at a CAGR of 1.3% from 2020 to 2025. Growth in this ma. Read more

MasterStream ERP Helps MAXAIR Automate Their Quoting In Response To Covid-19 Demand

April 27th, 2020

IRVINE, CA / CRWE PRESS RELEASE / April 27, 2020 / MasterStream ERP (www.masterstreamerp.com), the makers of leading quote-to-cash automation software for telecom providers, master agents and agents, today announced that it is joining the fight with . Read more

Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.

August 29th, 2016

Xiidra is the onlyprescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease Resources are available to support patients seeking information regarding coverage and savings offers Xiidra is t. Read more

Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

August 29th, 2016

1. Dramatic Decrease in Prostate Cancer and 2. Major Reduction in Need For BPH Prostate Surgery HASBROUCK HEIGHTS, N.J. / CRWE PRESS RELEASE / August 29, 2016 - Nymox Pharmaceutical Corporation (NASDAQ:NYMX) lead drug fexapotide which has been . Read more

New Long-Term Data Reinforce Safety Benefits of the World's Smallest Pacemaker

August 28th, 2016

Results Featured at ESC 2016 Demonstrate Consistent, Sustained Safety and Effectiveness for the Medtronic Micra TPS DUBLIN and ROME / CRWE PRESS RELEASE / AUGUST 28, 2016 - In the largest and longest clinical evaluation of leadless pacing patients. Read more

Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer in Europe

August 22nd, 2016

LOS ANGELES, Calif. / CRWE PRESS RELEASE / August 22, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced that the Marketing Authorization Application (MAA) for neratinib has been validated by the European Medicines A. Read more

Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides

August 17th, 2016

Toronto, Ontario / CRWE PRESS RELEASE / August 17, 2016 - Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the US Food . Read more

Medtronic Completes $20 Million Second Tranche Investment In Mazor Robotics

August 15th, 2016

CAESAREA, Israel / CRWE PRESS RELEASE / August 15, 2016 – Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a pioneer and a leader in the field of surgical guidance systems, today announced the completion of the second tranche of the equity inv. Read more

Load More Content